Risk of Violating Advertising and Legal Regulations
First written in FY2023. 7 of 10 entries say "Restated". Latest entry: FY2026.
The whole theme swung hardest in 2023: 2 of 6 companies on the "Worse" side.
0 other companies' latest entry also says "Reframed".
- FY2026ReframedAnnual report
「In particular, advertising and mail-order sales require compliance with the Act against Unjustifiable Premiums and Misleading Representations, the Pharmaceuticals and Medical Devices Act, the Health Promotion Act, the Act on Specified Commercial Transactions, the Act on the Protection of Personal Information and other laws. Depending on the business, compliance with laws and regulations relating to telecommunications, financial instruments transactions, crypto-assets and other areas may also be required.」
Regulatory risk, previously centered on advertising representations and the Pharmaceuticals and Medical Devices Act, has broadened into Group-wide legal and regulatory risk encompassing mail-order sales, personal information, telecommunications, crypto-assets and other areas. - FY2026-H1RestatedAnnual report
「Meanwhile, regulations governing web-marketing advertising under the Act against Unjustifiable Premiums and Misleading Representations and the Pharmaceuticals and Medical Devices Act are becoming stricter, requiring more cautious advertising expressions. Advertising efficiency may deteriorate when expressions are revised to be more conservative, but the Group complies with these laws and regulations, repeatedly conducts A/B tests and works to improve advertising efficiency.」
The Group continues to disclose tighter regulation, its potential impact on advertising efficiency and its response through A/B testing. - FY2025-H1RestatedAnnual report
「Meanwhile, regulations governing web-marketing advertising under the Act against Unjustifiable Premiums and Misleading Representations and the Pharmaceuticals and Medical Devices Act are becoming stricter, requiring more cautious advertising expressions. Advertising efficiency may deteriorate when expressions are revised to be more conservative, but the Group complies with these laws and regulations, repeatedly conducts A/B tests and works to improve advertising efficiency.」
The Group continues to disclose tighter regulation, its potential impact on advertising efficiency and its response through A/B testing. - FY2024RestatedAnnual report
「Meanwhile, regulations governing web-marketing advertising under the Act against Unjustifiable Premiums and Misleading Representations and the Pharmaceuticals and Medical Devices Act are becoming stricter, requiring more cautious advertising expressions.」
The Company continues to address tighter regulation and its potential impact on advertising efficiency through checklists and sample reviews. - FY2024-Q3RestatedAnnual report
「Meanwhile, regulations governing web-marketing advertising under the Act against Unjustifiable Premiums and Misleading Representations and the Pharmaceuticals and Medical Devices Act are becoming stricter, requiring more cautious advertising expressions. Advertising efficiency may deteriorate when expressions are revised to be more conservative, but the Company complies with these laws and regulations, repeatedly conducts A/B tests and works to improve advertising efficiency.」
The Company continues to disclose tighter regulation, its potential impact on advertising efficiency and its response through A/B testing. - FY2024-Q2RestatedAnnual report
「Meanwhile, regulations governing web-marketing advertising under the Act against Unjustifiable Premiums and Misleading Representations and the Pharmaceuticals and Medical Devices Act are becoming stricter, requiring more cautious advertising expressions. Advertising efficiency may deteriorate when expressions are revised to be more conservative, but the Company complies with these laws and regulations, repeatedly conducts A/B tests and works to improve advertising efficiency.」
The Company continues the previous quarter’s explanation of tighter regulation and its potential impact on advertising efficiency. - FY2024-Q1WorsenedAnnual report
「Meanwhile, regulations governing web-marketing advertising under the Act against Unjustifiable Premiums and Misleading Representations and the Pharmaceuticals and Medical Devices Act are becoming stricter, requiring more cautious advertising expressions. Advertising efficiency may deteriorate when expressions are revised to be more conservative, but the Company complies with these laws and regulations, repeatedly conducts A/B tests and works to improve advertising efficiency.」
The Company states that regulation under the two acts is becoming stricter and explicitly notes the possibility that more conservative advertising expressions may reduce advertising efficiency. - FY2023First statedAnnual report
「If, for any reason, we fail to respond promptly to amendments or developments in relevant laws and regulations, and the content, advertisements or media handled by the Company violate laws, regulations or public order and morals, or an event constituting a legal violation occurs, the Company’s credibility may decline and its business performance and financial condition may be affected.」
The Company addresses the Act against Unjustifiable Premiums and Misleading Representations, the Pharmaceuticals and Medical Devices Act, the Health Promotion Act and the Copyright Act through checklists, sample reviews, cooperation with specialists and its Risk and Compliance Committee.